nodes	percent_of_prediction	percent_of_DWPC	metapath
Clofarabine—Nucleic Acid Synthesis Inhibitors—Fluorouracil—skin cancer	0.701	1	CiPCiCtD
Clofarabine—ABCG2—Vismodegib—skin cancer	0.0666	0.34	CbGbCtD
Clofarabine—ABCG2—Vemurafenib—skin cancer	0.0526	0.269	CbGbCtD
Clofarabine—ABCG2—Dactinomycin—skin cancer	0.035	0.179	CbGbCtD
Clofarabine—ABCG2—Fluorouracil—skin cancer	0.0236	0.121	CbGbCtD
Clofarabine—ABCG2—Docetaxel—skin cancer	0.0181	0.0922	CbGbCtD
Clofarabine—RRM2—Sorafenib—Vismodegib—skin cancer	0.00171	1	CbGdCrCtD
Clofarabine—RRM1—hair follicle—skin cancer	0.00128	0.113	CbGeAlD
Clofarabine—RRM1—Fluoropyrimidine Activity—XRCC3—skin cancer	0.001	0.135	CbGpPWpGaD
Clofarabine—RRM1—nipple—skin cancer	0.000866	0.0767	CbGeAlD
Clofarabine—RRM2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000824	0.111	CbGpPWpGaD
Clofarabine—DCK—nipple—skin cancer	0.000673	0.0596	CbGeAlD
Clofarabine—RRM2—skin of body—skin cancer	0.000668	0.0591	CbGeAlD
Clofarabine—POLA1—mammalian vulva—skin cancer	0.000637	0.0564	CbGeAlD
Clofarabine—RRM2—mammalian vulva—skin cancer	0.000609	0.0539	CbGeAlD
Clofarabine—RRM1—skin of body—skin cancer	0.000555	0.0491	CbGeAlD
Clofarabine—RRM2—lymphoid tissue—skin cancer	0.000541	0.0479	CbGeAlD
Clofarabine—RRM2—female reproductive system—skin cancer	0.000521	0.0462	CbGeAlD
Clofarabine—RRM1—mammalian vulva—skin cancer	0.000506	0.0448	CbGeAlD
Clofarabine—RRM1—lymphoid tissue—skin cancer	0.000449	0.0398	CbGeAlD
Clofarabine—RRM2—head—skin cancer	0.000436	0.0386	CbGeAlD
Clofarabine—RRM1—female reproductive system—skin cancer	0.000433	0.0383	CbGeAlD
Clofarabine—DCK—mammalian vulva—skin cancer	0.000393	0.0348	CbGeAlD
Clofarabine—RRM1—E2F transcription factor network—XRCC1—skin cancer	0.000385	0.052	CbGpPWpGaD
Clofarabine—RRM1—head—skin cancer	0.000362	0.032	CbGeAlD
Clofarabine—RRM1—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000352	0.0475	CbGpPWpGaD
Clofarabine—DCK—lymphoid tissue—skin cancer	0.000349	0.0309	CbGeAlD
Clofarabine—DCK—female reproductive system—skin cancer	0.000336	0.0298	CbGeAlD
Clofarabine—POLA1—lymph node—skin cancer	0.000319	0.0283	CbGeAlD
Clofarabine—RRM2—E2F transcription factor network—XRCC1—skin cancer	0.000317	0.0428	CbGpPWpGaD
Clofarabine—ABCG2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000308	0.0416	CbGpPWpGaD
Clofarabine—RRM2—lymph node—skin cancer	0.000305	0.027	CbGeAlD
Clofarabine—RRM2—Fluoropyrimidine Activity—ERCC2—skin cancer	0.00029	0.0391	CbGpPWpGaD
Clofarabine—DCK—head—skin cancer	0.000281	0.0249	CbGeAlD
Clofarabine—RRM1—lymph node—skin cancer	0.000253	0.0224	CbGeAlD
Clofarabine—ABCG2—mammalian vulva—skin cancer	0.000219	0.0194	CbGeAlD
Clofarabine—POLA1—E2F transcription factor network—XRCC1—skin cancer	0.000217	0.0293	CbGpPWpGaD
Clofarabine—POLA1—Extension of Telomeres—TERT—skin cancer	0.000206	0.0278	CbGpPWpGaD
Clofarabine—DCK—lymph node—skin cancer	0.000197	0.0174	CbGeAlD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000196	0.0264	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000149	0.0201	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000141	0.019	CbGpPWpGaD
Clofarabine—RRM1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000136	0.0184	CbGpPWpGaD
Clofarabine—RRM1—Fluoropyrimidine Activity—TP53—skin cancer	0.000126	0.017	CbGpPWpGaD
Clofarabine—RRM1—E2F transcription factor network—CDKN2A—skin cancer	0.00012	0.0161	CbGpPWpGaD
Clofarabine—RRM2—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000112	0.0151	CbGpPWpGaD
Clofarabine—ABCG2—lymph node—skin cancer	0.00011	0.00972	CbGeAlD
Clofarabine—ABCG2—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000108	0.0146	CbGpPWpGaD
Clofarabine—Pneumonia—Fluorouracil—skin cancer	0.000108	0.00132	CcSEcCtD
Clofarabine—Erythema—Bleomycin—skin cancer	0.000108	0.00132	CcSEcCtD
Clofarabine—Decreased appetite—Imiquimod—skin cancer	0.000108	0.00131	CcSEcCtD
Clofarabine—Infestation NOS—Fluorouracil—skin cancer	0.000108	0.00131	CcSEcCtD
Clofarabine—Infestation—Fluorouracil—skin cancer	0.000108	0.00131	CcSEcCtD
Clofarabine—Flushing—Dactinomycin—skin cancer	0.000108	0.00131	CcSEcCtD
Clofarabine—Hypersensitivity—Vemurafenib—skin cancer	0.000107	0.00131	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Imiquimod—skin cancer	0.000107	0.00131	CcSEcCtD
Clofarabine—Fatigue—Imiquimod—skin cancer	0.000107	0.0013	CcSEcCtD
Clofarabine—Pain—Imiquimod—skin cancer	0.000106	0.00129	CcSEcCtD
Clofarabine—Neuropathy peripheral—Fluorouracil—skin cancer	0.000106	0.00128	CcSEcCtD
Clofarabine—Haemoglobin—Temozolomide—skin cancer	0.000105	0.00128	CcSEcCtD
Clofarabine—Stomatitis—Fluorouracil—skin cancer	0.000105	0.00128	CcSEcCtD
Clofarabine—Haemorrhage—Temozolomide—skin cancer	0.000105	0.00128	CcSEcCtD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000105	0.0141	CbGpPWpGaD
Clofarabine—Asthenia—Vemurafenib—skin cancer	0.000105	0.00127	CcSEcCtD
Clofarabine—Chills—Dactinomycin—skin cancer	0.000104	0.00127	CcSEcCtD
Clofarabine—Urinary tract disorder—Temozolomide—skin cancer	0.000104	0.00126	CcSEcCtD
Clofarabine—RRM2—Fluoropyrimidine Activity—TP53—skin cancer	0.000104	0.014	CbGpPWpGaD
Clofarabine—Oedema peripheral—Temozolomide—skin cancer	0.000103	0.00126	CcSEcCtD
Clofarabine—Pruritus—Vemurafenib—skin cancer	0.000103	0.00125	CcSEcCtD
Clofarabine—Connective tissue disorder—Temozolomide—skin cancer	0.000103	0.00125	CcSEcCtD
Clofarabine—Lethargy—Docetaxel—skin cancer	0.000103	0.00125	CcSEcCtD
Clofarabine—Urethral disorder—Temozolomide—skin cancer	0.000103	0.00125	CcSEcCtD
Clofarabine—Alopecia—Dactinomycin—skin cancer	0.000103	0.00125	CcSEcCtD
Clofarabine—Feeling abnormal—Imiquimod—skin cancer	0.000103	0.00125	CcSEcCtD
Clofarabine—Gastrointestinal pain—Imiquimod—skin cancer	0.000102	0.00124	CcSEcCtD
Clofarabine—Epistaxis—Fluorouracil—skin cancer	0.000102	0.00124	CcSEcCtD
Clofarabine—Sinusitis—Fluorouracil—skin cancer	0.000101	0.00123	CcSEcCtD
Clofarabine—Erythema—Dactinomycin—skin cancer	0.000101	0.00123	CcSEcCtD
Clofarabine—Pain in extremity—Docetaxel—skin cancer	0.000101	0.00123	CcSEcCtD
Clofarabine—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000101	0.00123	CcSEcCtD
Clofarabine—Anaemia—Bleomycin—skin cancer	0.0001	0.00122	CcSEcCtD
Clofarabine—Diarrhoea—Vemurafenib—skin cancer	9.98e-05	0.00121	CcSEcCtD
Clofarabine—Erythema multiforme—Temozolomide—skin cancer	9.92e-05	0.00121	CcSEcCtD
Clofarabine—RRM2—E2F transcription factor network—CDKN2A—skin cancer	9.86e-05	0.0133	CbGpPWpGaD
Clofarabine—Abdominal pain—Imiquimod—skin cancer	9.83e-05	0.0012	CcSEcCtD
Clofarabine—Body temperature increased—Imiquimod—skin cancer	9.83e-05	0.0012	CcSEcCtD
Clofarabine—Cardiac disorder—Temozolomide—skin cancer	9.74e-05	0.00118	CcSEcCtD
Clofarabine—Flushing—Temozolomide—skin cancer	9.74e-05	0.00118	CcSEcCtD
Clofarabine—Haemoglobin—Fluorouracil—skin cancer	9.72e-05	0.00118	CcSEcCtD
Clofarabine—Leukopenia—Bleomycin—skin cancer	9.69e-05	0.00118	CcSEcCtD
Clofarabine—Haemorrhage—Fluorouracil—skin cancer	9.67e-05	0.00118	CcSEcCtD
Clofarabine—Dizziness—Vemurafenib—skin cancer	9.65e-05	0.00117	CcSEcCtD
Clofarabine—Angiopathy—Temozolomide—skin cancer	9.52e-05	0.00116	CcSEcCtD
Clofarabine—Immune system disorder—Temozolomide—skin cancer	9.48e-05	0.00115	CcSEcCtD
Clofarabine—Mediastinal disorder—Temozolomide—skin cancer	9.46e-05	0.00115	CcSEcCtD
Clofarabine—Cough—Bleomycin—skin cancer	9.45e-05	0.00115	CcSEcCtD
Clofarabine—Chills—Temozolomide—skin cancer	9.41e-05	0.00114	CcSEcCtD
Clofarabine—Dehydration—Docetaxel—skin cancer	9.38e-05	0.00114	CcSEcCtD
Clofarabine—POLA1—Telomere Maintenance—TERT—skin cancer	9.35e-05	0.0126	CbGpPWpGaD
Clofarabine—Anaemia—Dactinomycin—skin cancer	9.33e-05	0.00114	CcSEcCtD
Clofarabine—Vomiting—Vemurafenib—skin cancer	9.27e-05	0.00113	CcSEcCtD
Clofarabine—Alopecia—Temozolomide—skin cancer	9.27e-05	0.00113	CcSEcCtD
Clofarabine—Dry skin—Docetaxel—skin cancer	9.25e-05	0.00112	CcSEcCtD
Clofarabine—Myalgia—Bleomycin—skin cancer	9.22e-05	0.00112	CcSEcCtD
Clofarabine—Abdominal pain upper—Docetaxel—skin cancer	9.21e-05	0.00112	CcSEcCtD
Clofarabine—Rash—Vemurafenib—skin cancer	9.2e-05	0.00112	CcSEcCtD
Clofarabine—Mental disorder—Temozolomide—skin cancer	9.19e-05	0.00112	CcSEcCtD
Clofarabine—Dermatitis—Vemurafenib—skin cancer	9.19e-05	0.00112	CcSEcCtD
Clofarabine—Hypersensitivity—Imiquimod—skin cancer	9.17e-05	0.00111	CcSEcCtD
Clofarabine—Headache—Vemurafenib—skin cancer	9.14e-05	0.00111	CcSEcCtD
Clofarabine—Malnutrition—Temozolomide—skin cancer	9.13e-05	0.00111	CcSEcCtD
Clofarabine—Erythema—Temozolomide—skin cancer	9.13e-05	0.00111	CcSEcCtD
Clofarabine—Aspartate aminotransferase increased—Docetaxel—skin cancer	9.08e-05	0.0011	CcSEcCtD
Clofarabine—Toxic epidermal necrolysis—Docetaxel—skin cancer	9.08e-05	0.0011	CcSEcCtD
Clofarabine—Leukopenia—Dactinomycin—skin cancer	9.04e-05	0.0011	CcSEcCtD
Clofarabine—Asthenia—Imiquimod—skin cancer	8.93e-05	0.00109	CcSEcCtD
Clofarabine—Alanine aminotransferase increased—Docetaxel—skin cancer	8.9e-05	0.00108	CcSEcCtD
Clofarabine—Oedema—Bleomycin—skin cancer	8.84e-05	0.00107	CcSEcCtD
Clofarabine—Back pain—Temozolomide—skin cancer	8.84e-05	0.00107	CcSEcCtD
Clofarabine—Pruritus—Imiquimod—skin cancer	8.8e-05	0.00107	CcSEcCtD
Clofarabine—Infection—Bleomycin—skin cancer	8.78e-05	0.00107	CcSEcCtD
Clofarabine—Nausea—Vemurafenib—skin cancer	8.66e-05	0.00105	CcSEcCtD
Clofarabine—Thrombocytopenia—Bleomycin—skin cancer	8.65e-05	0.00105	CcSEcCtD
Clofarabine—Myalgia—Dactinomycin—skin cancer	8.6e-05	0.00105	CcSEcCtD
Clofarabine—Tremor—Temozolomide—skin cancer	8.56e-05	0.00104	CcSEcCtD
Clofarabine—Alopecia—Fluorouracil—skin cancer	8.54e-05	0.00104	CcSEcCtD
Clofarabine—Diarrhoea—Imiquimod—skin cancer	8.51e-05	0.00104	CcSEcCtD
Clofarabine—Anaemia—Temozolomide—skin cancer	8.44e-05	0.00103	CcSEcCtD
Clofarabine—Anorexia—Bleomycin—skin cancer	8.42e-05	0.00102	CcSEcCtD
Clofarabine—Erythema—Fluorouracil—skin cancer	8.42e-05	0.00102	CcSEcCtD
Clofarabine—Agitation—Temozolomide—skin cancer	8.39e-05	0.00102	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	8.38e-05	0.0113	CbGpPWpGaD
Clofarabine—Pancytopenia—Docetaxel—skin cancer	8.28e-05	0.00101	CcSEcCtD
Clofarabine—Hypotension—Bleomycin—skin cancer	8.26e-05	0.001	CcSEcCtD
Clofarabine—Oedema—Dactinomycin—skin cancer	8.24e-05	0.001	CcSEcCtD
Clofarabine—Dizziness—Imiquimod—skin cancer	8.23e-05	0.001	CcSEcCtD
Clofarabine—Infection—Dactinomycin—skin cancer	8.19e-05	0.000996	CcSEcCtD
Clofarabine—Leukopenia—Temozolomide—skin cancer	8.18e-05	0.000994	CcSEcCtD
Clofarabine—Neutropenia—Docetaxel—skin cancer	8.15e-05	0.000991	CcSEcCtD
Clofarabine—Thrombocytopenia—Dactinomycin—skin cancer	8.07e-05	0.000981	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Bleomycin—skin cancer	8.05e-05	0.000979	CcSEcCtD
Clofarabine—Cough—Temozolomide—skin cancer	7.97e-05	0.000969	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	7.95e-05	0.0107	CbGpPWpGaD
Clofarabine—Paraesthesia—Bleomycin—skin cancer	7.94e-05	0.000965	CcSEcCtD
Clofarabine—Vomiting—Imiquimod—skin cancer	7.91e-05	0.000962	CcSEcCtD
Clofarabine—Weight decreased—Docetaxel—skin cancer	7.89e-05	0.000959	CcSEcCtD
Clofarabine—Hypertension—Temozolomide—skin cancer	7.89e-05	0.000959	CcSEcCtD
Clofarabine—RRM2—Mitotic G1-G1/S phases—CDK4—skin cancer	7.89e-05	0.0106	CbGpPWpGaD
Clofarabine—Dyspnoea—Bleomycin—skin cancer	7.88e-05	0.000958	CcSEcCtD
Clofarabine—Anorexia—Dactinomycin—skin cancer	7.86e-05	0.000955	CcSEcCtD
Clofarabine—Rash—Imiquimod—skin cancer	7.84e-05	0.000954	CcSEcCtD
Clofarabine—Dermatitis—Imiquimod—skin cancer	7.84e-05	0.000953	CcSEcCtD
Clofarabine—Pneumonia—Docetaxel—skin cancer	7.82e-05	0.000951	CcSEcCtD
Clofarabine—Headache—Imiquimod—skin cancer	7.79e-05	0.000948	CcSEcCtD
Clofarabine—POLA1—Chromosome Maintenance—TERT—skin cancer	7.79e-05	0.0105	CbGpPWpGaD
Clofarabine—Anaemia—Fluorouracil—skin cancer	7.78e-05	0.000946	CcSEcCtD
Clofarabine—Myalgia—Temozolomide—skin cancer	7.78e-05	0.000946	CcSEcCtD
Clofarabine—Arthralgia—Temozolomide—skin cancer	7.78e-05	0.000946	CcSEcCtD
Clofarabine—Infestation NOS—Docetaxel—skin cancer	7.77e-05	0.000945	CcSEcCtD
Clofarabine—Infestation—Docetaxel—skin cancer	7.77e-05	0.000945	CcSEcCtD
Clofarabine—Anxiety—Temozolomide—skin cancer	7.75e-05	0.000942	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	7.72e-05	0.000939	CcSEcCtD
Clofarabine—Stevens-Johnson syndrome—Docetaxel—skin cancer	7.71e-05	0.000937	CcSEcCtD
Clofarabine—Decreased appetite—Bleomycin—skin cancer	7.68e-05	0.000934	CcSEcCtD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	7.67e-05	0.0103	CbGpPWpGaD
Clofarabine—Renal failure—Docetaxel—skin cancer	7.64e-05	0.000929	CcSEcCtD
Clofarabine—Neuropathy peripheral—Docetaxel—skin cancer	7.62e-05	0.000927	CcSEcCtD
Clofarabine—Stomatitis—Docetaxel—skin cancer	7.58e-05	0.000921	CcSEcCtD
Clofarabine—Jaundice—Docetaxel—skin cancer	7.58e-05	0.000921	CcSEcCtD
Clofarabine—Pain—Bleomycin—skin cancer	7.56e-05	0.000919	CcSEcCtD
Clofarabine—Leukopenia—Fluorouracil—skin cancer	7.53e-05	0.000916	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Dactinomycin—skin cancer	7.51e-05	0.000913	CcSEcCtD
Clofarabine—Oedema—Temozolomide—skin cancer	7.45e-05	0.000907	CcSEcCtD
Clofarabine—Infection—Temozolomide—skin cancer	7.41e-05	0.000901	CcSEcCtD
Clofarabine—Nausea—Imiquimod—skin cancer	7.39e-05	0.000899	CcSEcCtD
Clofarabine—Hepatobiliary disease—Docetaxel—skin cancer	7.35e-05	0.000894	CcSEcCtD
Clofarabine—Epistaxis—Docetaxel—skin cancer	7.33e-05	0.000892	CcSEcCtD
Clofarabine—Nervous system disorder—Temozolomide—skin cancer	7.31e-05	0.000889	CcSEcCtD
Clofarabine—Thrombocytopenia—Temozolomide—skin cancer	7.3e-05	0.000888	CcSEcCtD
Clofarabine—Feeling abnormal—Bleomycin—skin cancer	7.28e-05	0.000886	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	7.25e-05	0.00979	CbGpPWpGaD
Clofarabine—Skin disorder—Temozolomide—skin cancer	7.24e-05	0.000881	CcSEcCtD
Clofarabine—Hyperhidrosis—Temozolomide—skin cancer	7.21e-05	0.000876	CcSEcCtD
Clofarabine—Myalgia—Fluorouracil—skin cancer	7.17e-05	0.000871	CcSEcCtD
Clofarabine—Decreased appetite—Dactinomycin—skin cancer	7.16e-05	0.000871	CcSEcCtD
Clofarabine—Fatigue—Dactinomycin—skin cancer	7.11e-05	0.000864	CcSEcCtD
Clofarabine—Anorexia—Temozolomide—skin cancer	7.11e-05	0.000864	CcSEcCtD
Clofarabine—Pain—Dactinomycin—skin cancer	7.05e-05	0.000857	CcSEcCtD
Clofarabine—Haemoglobin—Docetaxel—skin cancer	7.01e-05	0.000853	CcSEcCtD
Clofarabine—Body temperature increased—Bleomycin—skin cancer	6.99e-05	0.00085	CcSEcCtD
Clofarabine—Haemorrhage—Docetaxel—skin cancer	6.98e-05	0.000849	CcSEcCtD
Clofarabine—Urinary tract disorder—Docetaxel—skin cancer	6.89e-05	0.000838	CcSEcCtD
Clofarabine—Oedema peripheral—Docetaxel—skin cancer	6.87e-05	0.000836	CcSEcCtD
Clofarabine—Oedema—Fluorouracil—skin cancer	6.87e-05	0.000835	CcSEcCtD
Clofarabine—Connective tissue disorder—Docetaxel—skin cancer	6.86e-05	0.000834	CcSEcCtD
Clofarabine—Urethral disorder—Docetaxel—skin cancer	6.84e-05	0.000832	CcSEcCtD
Clofarabine—Infection—Fluorouracil—skin cancer	6.82e-05	0.00083	CcSEcCtD
Clofarabine—Feeling abnormal—Dactinomycin—skin cancer	6.79e-05	0.000826	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Temozolomide—skin cancer	6.79e-05	0.000826	CcSEcCtD
Clofarabine—POLA1—E2F transcription factor network—CDKN2A—skin cancer	6.74e-05	0.0091	CbGpPWpGaD
Clofarabine—Gastrointestinal pain—Dactinomycin—skin cancer	6.74e-05	0.00082	CcSEcCtD
Clofarabine—Nervous system disorder—Fluorouracil—skin cancer	6.74e-05	0.000819	CcSEcCtD
Clofarabine—Thrombocytopenia—Fluorouracil—skin cancer	6.73e-05	0.000818	CcSEcCtD
Clofarabine—Tachycardia—Fluorouracil—skin cancer	6.7e-05	0.000815	CcSEcCtD
Clofarabine—Paraesthesia—Temozolomide—skin cancer	6.69e-05	0.000814	CcSEcCtD
Clofarabine—Dyspnoea—Temozolomide—skin cancer	6.65e-05	0.000808	CcSEcCtD
Clofarabine—Somnolence—Temozolomide—skin cancer	6.63e-05	0.000806	CcSEcCtD
Clofarabine—Erythema multiforme—Docetaxel—skin cancer	6.6e-05	0.000802	CcSEcCtD
Clofarabine—Anorexia—Fluorouracil—skin cancer	6.55e-05	0.000796	CcSEcCtD
Clofarabine—Abdominal pain—Dactinomycin—skin cancer	6.52e-05	0.000792	CcSEcCtD
Clofarabine—Body temperature increased—Dactinomycin—skin cancer	6.52e-05	0.000792	CcSEcCtD
Clofarabine—Hypersensitivity—Bleomycin—skin cancer	6.51e-05	0.000792	CcSEcCtD
Clofarabine—Decreased appetite—Temozolomide—skin cancer	6.48e-05	0.000788	CcSEcCtD
Clofarabine—Flushing—Docetaxel—skin cancer	6.48e-05	0.000788	CcSEcCtD
Clofarabine—Cardiac disorder—Docetaxel—skin cancer	6.48e-05	0.000788	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Temozolomide—skin cancer	6.44e-05	0.000783	CcSEcCtD
Clofarabine—Fatigue—Temozolomide—skin cancer	6.43e-05	0.000782	CcSEcCtD
Clofarabine—Hypotension—Fluorouracil—skin cancer	6.42e-05	0.00078	CcSEcCtD
Clofarabine—Pain—Temozolomide—skin cancer	6.37e-05	0.000775	CcSEcCtD
Clofarabine—Asthenia—Bleomycin—skin cancer	6.34e-05	0.000771	CcSEcCtD
Clofarabine—Angiopathy—Docetaxel—skin cancer	6.33e-05	0.00077	CcSEcCtD
Clofarabine—Immune system disorder—Docetaxel—skin cancer	6.3e-05	0.000766	CcSEcCtD
Clofarabine—Mediastinal disorder—Docetaxel—skin cancer	6.29e-05	0.000765	CcSEcCtD
Clofarabine—Chills—Docetaxel—skin cancer	6.26e-05	0.000761	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Fluorouracil—skin cancer	6.26e-05	0.000761	CcSEcCtD
Clofarabine—Pruritus—Bleomycin—skin cancer	6.25e-05	0.00076	CcSEcCtD
Clofarabine—Paraesthesia—Fluorouracil—skin cancer	6.17e-05	0.00075	CcSEcCtD
Clofarabine—Alopecia—Docetaxel—skin cancer	6.17e-05	0.00075	CcSEcCtD
Clofarabine—Feeling abnormal—Temozolomide—skin cancer	6.14e-05	0.000747	CcSEcCtD
Clofarabine—Dyspnoea—Fluorouracil—skin cancer	6.12e-05	0.000745	CcSEcCtD
Clofarabine—Mental disorder—Docetaxel—skin cancer	6.11e-05	0.000743	CcSEcCtD
Clofarabine—Somnolence—Fluorouracil—skin cancer	6.11e-05	0.000743	CcSEcCtD
Clofarabine—Gastrointestinal pain—Temozolomide—skin cancer	6.1e-05	0.000741	CcSEcCtD
Clofarabine—Malnutrition—Docetaxel—skin cancer	6.07e-05	0.000739	CcSEcCtD
Clofarabine—Erythema—Docetaxel—skin cancer	6.07e-05	0.000739	CcSEcCtD
Clofarabine—Hypersensitivity—Dactinomycin—skin cancer	6.07e-05	0.000738	CcSEcCtD
Clofarabine—RRM2—Mitotic G1-G1/S phases—CDKN2A—skin cancer	6.03e-05	0.00813	CbGpPWpGaD
Clofarabine—Decreased appetite—Fluorouracil—skin cancer	5.97e-05	0.000726	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Fluorouracil—skin cancer	5.93e-05	0.000721	CcSEcCtD
Clofarabine—Asthenia—Dactinomycin—skin cancer	5.91e-05	0.000719	CcSEcCtD
Clofarabine—Abdominal pain—Temozolomide—skin cancer	5.89e-05	0.000717	CcSEcCtD
Clofarabine—Body temperature increased—Temozolomide—skin cancer	5.89e-05	0.000717	CcSEcCtD
Clofarabine—Back pain—Docetaxel—skin cancer	5.88e-05	0.000714	CcSEcCtD
Clofarabine—Pain—Fluorouracil—skin cancer	5.87e-05	0.000714	CcSEcCtD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—TERT—skin cancer	5.84e-05	0.00788	CbGpPWpGaD
Clofarabine—POLA1—S Phase—CDK4—skin cancer	5.81e-05	0.00784	CbGpPWpGaD
Clofarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	5.79e-05	0.00781	CbGpPWpGaD
Clofarabine—Feeling abnormal—Fluorouracil—skin cancer	5.66e-05	0.000688	CcSEcCtD
Clofarabine—Diarrhoea—Dactinomycin—skin cancer	5.64e-05	0.000686	CcSEcCtD
Clofarabine—Vomiting—Bleomycin—skin cancer	5.62e-05	0.000683	CcSEcCtD
Clofarabine—Anaemia—Docetaxel—skin cancer	5.61e-05	0.000683	CcSEcCtD
Clofarabine—Rash—Bleomycin—skin cancer	5.57e-05	0.000678	CcSEcCtD
Clofarabine—Dermatitis—Bleomycin—skin cancer	5.57e-05	0.000677	CcSEcCtD
Clofarabine—Hypersensitivity—Temozolomide—skin cancer	5.49e-05	0.000668	CcSEcCtD
Clofarabine—Leukopenia—Docetaxel—skin cancer	5.44e-05	0.000661	CcSEcCtD
Clofarabine—Body temperature increased—Fluorouracil—skin cancer	5.43e-05	0.00066	CcSEcCtD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CDK4—skin cancer	5.39e-05	0.00728	CbGpPWpGaD
Clofarabine—Asthenia—Temozolomide—skin cancer	5.35e-05	0.00065	CcSEcCtD
Clofarabine—Cough—Docetaxel—skin cancer	5.3e-05	0.000645	CcSEcCtD
Clofarabine—Pruritus—Temozolomide—skin cancer	5.27e-05	0.000641	CcSEcCtD
Clofarabine—Nausea—Bleomycin—skin cancer	5.25e-05	0.000638	CcSEcCtD
Clofarabine—Hypertension—Docetaxel—skin cancer	5.24e-05	0.000638	CcSEcCtD
Clofarabine—Vomiting—Dactinomycin—skin cancer	5.24e-05	0.000637	CcSEcCtD
Clofarabine—Rash—Dactinomycin—skin cancer	5.2e-05	0.000632	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	5.18e-05	0.00699	CbGpPWpGaD
Clofarabine—Arthralgia—Docetaxel—skin cancer	5.17e-05	0.000629	CcSEcCtD
Clofarabine—Myalgia—Docetaxel—skin cancer	5.17e-05	0.000629	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	5.14e-05	0.000625	CcSEcCtD
Clofarabine—Diarrhoea—Temozolomide—skin cancer	5.1e-05	0.00062	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—MLH1—skin cancer	5.09e-05	0.00686	CbGpPWpGaD
Clofarabine—Hypersensitivity—Fluorouracil—skin cancer	5.06e-05	0.000615	CcSEcCtD
Clofarabine—RRM1—Metabolism—PLIN2—skin cancer	5.05e-05	0.00682	CbGpPWpGaD
Clofarabine—Oedema—Docetaxel—skin cancer	4.96e-05	0.000603	CcSEcCtD
Clofarabine—Dizziness—Temozolomide—skin cancer	4.93e-05	0.000599	CcSEcCtD
Clofarabine—Infection—Docetaxel—skin cancer	4.93e-05	0.000599	CcSEcCtD
Clofarabine—Nausea—Dactinomycin—skin cancer	4.9e-05	0.000595	CcSEcCtD
Clofarabine—Nervous system disorder—Docetaxel—skin cancer	4.86e-05	0.000591	CcSEcCtD
Clofarabine—Pruritus—Fluorouracil—skin cancer	4.86e-05	0.000591	CcSEcCtD
Clofarabine—Thrombocytopenia—Docetaxel—skin cancer	4.85e-05	0.00059	CcSEcCtD
Clofarabine—Tachycardia—Docetaxel—skin cancer	4.84e-05	0.000588	CcSEcCtD
Clofarabine—Skin disorder—Docetaxel—skin cancer	4.82e-05	0.000586	CcSEcCtD
Clofarabine—RRM2—Retinoblastoma (RB) in Cancer—TP53—skin cancer	4.77e-05	0.00643	CbGpPWpGaD
Clofarabine—Vomiting—Temozolomide—skin cancer	4.74e-05	0.000576	CcSEcCtD
Clofarabine—Anorexia—Docetaxel—skin cancer	4.73e-05	0.000575	CcSEcCtD
Clofarabine—Rash—Temozolomide—skin cancer	4.7e-05	0.000572	CcSEcCtD
Clofarabine—Diarrhoea—Fluorouracil—skin cancer	4.7e-05	0.000571	CcSEcCtD
Clofarabine—Dermatitis—Temozolomide—skin cancer	4.7e-05	0.000571	CcSEcCtD
Clofarabine—Headache—Temozolomide—skin cancer	4.67e-05	0.000568	CcSEcCtD
Clofarabine—Hypotension—Docetaxel—skin cancer	4.63e-05	0.000563	CcSEcCtD
Clofarabine—Dizziness—Fluorouracil—skin cancer	4.54e-05	0.000552	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Docetaxel—skin cancer	4.52e-05	0.000549	CcSEcCtD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—skin cancer	4.45e-05	0.00601	CbGpPWpGaD
Clofarabine—Paraesthesia—Docetaxel—skin cancer	4.45e-05	0.000541	CcSEcCtD
Clofarabine—Nausea—Temozolomide—skin cancer	4.43e-05	0.000538	CcSEcCtD
Clofarabine—Dyspnoea—Docetaxel—skin cancer	4.42e-05	0.000537	CcSEcCtD
Clofarabine—Somnolence—Docetaxel—skin cancer	4.41e-05	0.000536	CcSEcCtD
Clofarabine—Vomiting—Fluorouracil—skin cancer	4.37e-05	0.000531	CcSEcCtD
Clofarabine—Rash—Fluorouracil—skin cancer	4.33e-05	0.000527	CcSEcCtD
Clofarabine—Dermatitis—Fluorouracil—skin cancer	4.33e-05	0.000526	CcSEcCtD
Clofarabine—Decreased appetite—Docetaxel—skin cancer	4.31e-05	0.000524	CcSEcCtD
Clofarabine—Headache—Fluorouracil—skin cancer	4.3e-05	0.000523	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Docetaxel—skin cancer	4.28e-05	0.00052	CcSEcCtD
Clofarabine—Fatigue—Docetaxel—skin cancer	4.27e-05	0.00052	CcSEcCtD
Clofarabine—Pain—Docetaxel—skin cancer	4.24e-05	0.000516	CcSEcCtD
Clofarabine—RRM2—Metabolism—PLIN2—skin cancer	4.16e-05	0.00561	CbGpPWpGaD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—skin cancer	4.12e-05	0.00556	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	4.09e-05	0.00551	CbGpPWpGaD
Clofarabine—Feeling abnormal—Docetaxel—skin cancer	4.09e-05	0.000497	CcSEcCtD
Clofarabine—Nausea—Fluorouracil—skin cancer	4.08e-05	0.000496	CcSEcCtD
Clofarabine—RRM1—Metabolism—CSPG4—skin cancer	4.07e-05	0.00549	CbGpPWpGaD
Clofarabine—Gastrointestinal pain—Docetaxel—skin cancer	4.05e-05	0.000493	CcSEcCtD
Clofarabine—Abdominal pain—Docetaxel—skin cancer	3.92e-05	0.000477	CcSEcCtD
Clofarabine—Body temperature increased—Docetaxel—skin cancer	3.92e-05	0.000477	CcSEcCtD
Clofarabine—DCK—Metabolism—PLIN2—skin cancer	3.89e-05	0.00525	CbGpPWpGaD
Clofarabine—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	3.87e-05	0.00522	CbGpPWpGaD
Clofarabine—Hypersensitivity—Docetaxel—skin cancer	3.65e-05	0.000444	CcSEcCtD
Clofarabine—Asthenia—Docetaxel—skin cancer	3.56e-05	0.000433	CcSEcCtD
Clofarabine—Pruritus—Docetaxel—skin cancer	3.51e-05	0.000427	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—MLH1—skin cancer	3.48e-05	0.00469	CbGpPWpGaD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	3.47e-05	0.00468	CbGpPWpGaD
Clofarabine—Diarrhoea—Docetaxel—skin cancer	3.39e-05	0.000412	CcSEcCtD
Clofarabine—RRM2—Metabolism—CSPG4—skin cancer	3.35e-05	0.00452	CbGpPWpGaD
Clofarabine—Dizziness—Docetaxel—skin cancer	3.28e-05	0.000399	CcSEcCtD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—skin cancer	3.26e-05	0.0044	CbGpPWpGaD
Clofarabine—Vomiting—Docetaxel—skin cancer	3.15e-05	0.000383	CcSEcCtD
Clofarabine—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	3.15e-05	0.00425	CbGpPWpGaD
Clofarabine—DCK—Metabolism—CSPG4—skin cancer	3.13e-05	0.00423	CbGpPWpGaD
Clofarabine—Rash—Docetaxel—skin cancer	3.13e-05	0.00038	CcSEcCtD
Clofarabine—Dermatitis—Docetaxel—skin cancer	3.12e-05	0.00038	CcSEcCtD
Clofarabine—Headache—Docetaxel—skin cancer	3.11e-05	0.000378	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	3.09e-05	0.00416	CbGpPWpGaD
Clofarabine—Nausea—Docetaxel—skin cancer	2.94e-05	0.000358	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.92e-05	0.00394	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CDK4—skin cancer	2.89e-05	0.0039	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—TERT—skin cancer	2.89e-05	0.0039	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—ENO2—skin cancer	2.77e-05	0.00373	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CDK4—skin cancer	2.59e-05	0.00349	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ENO2—skin cancer	2.28e-05	0.00308	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CDKN2A—skin cancer	2.21e-05	0.00298	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ENO2—skin cancer	2.13e-05	0.00287	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CDK4—skin cancer	1.98e-05	0.00267	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CDKN2A—skin cancer	1.98e-05	0.00267	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—TERT—skin cancer	1.98e-05	0.00267	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.96e-05	0.00264	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CDK4—skin cancer	1.77e-05	0.00239	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.74e-05	0.00234	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—ERCC2—skin cancer	1.61e-05	0.00217	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PLIN2—skin cancer	1.56e-05	0.0021	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—skin cancer	1.51e-05	0.00204	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CDKN2A—skin cancer	1.35e-05	0.00182	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ERCC2—skin cancer	1.32e-05	0.00179	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—CSPG4—skin cancer	1.25e-05	0.00169	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ERCC2—skin cancer	1.24e-05	0.00167	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—TP53—skin cancer	1.1e-05	0.00148	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PTGS2—skin cancer	9.64e-06	0.0013	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ENO2—skin cancer	8.53e-06	0.00115	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PTGS2—skin cancer	7.94e-06	0.00107	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—TP53—skin cancer	7.52e-06	0.00102	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PTGS2—skin cancer	7.42e-06	0.001	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ERCC2—skin cancer	4.95e-06	0.000668	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PTGS2—skin cancer	2.97e-06	0.000401	CbGpPWpGaD
